Monte Rosa Therapeutics Inc. has entered into a licensing agreement with Novartis, potentially worth up to $5.7 billion, to develop novel degraders for immune-mediated diseases.

Monte Rosa Therapeutics is pioneering a new approach to disease treatment with its molecular glue technology, aiming to degrade disease-causing proteins and transform patient outcomes.

Monte Rosa Therapeutics is pioneering a new approach to disease treatment with its molecular glues, which aim to dismantle disease-causing proteins and potentially transform patient care.